Friday - April 24, 2026

Category Archives: Pharmaceuticals & Biotech

iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight

iPSC-Derived NK Cells Pipeline The iPSC-derived NK cells therapeutic landscape is entering a transformative phase, driven by cutting-edge advancements in cellular engineering, scalable manufacturing, and next-generation immuno-oncology approaches. iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ … Continue reading →

Idiopathic Pulmonary Fibrosis Pipeline Progresses as 80+ Pharma Companies Advance Novel Lung Disease Therapies, Finds DelveInsight | Bristol-Myers Squibb, Genentech, Tvardi Therapeutics, Melius Pharma

Idiopathic Pulmonary Fibrosis Pipeline Insight There are 80+ key companies, including Bristol-Myers Squibb, Genentech, Tvardi Therapeutics, Melius Pharma, Resproly, and others, developing therapies for Idiopathic Pulmonary Fibrosis, with Bristol-Myers Squibb having its IPF drug candidate in the most advanced Phase … Continue reading →

B-cell Lymphoma Pipeline Grows as 295+ Pharma Companies Advance Novel Lymphoma Therapies, Finds DelveInsight | Bristol Myers Squibb, Roche, Nektar Therapeutics, Miltenyi Biotec

B-cell Lymphoma Pipeline Insight There are 295+ key companies, including Bristol Myers Squibb, Roche, Nektar Therapeutics, Miltenyi Biotec, and others, developing therapies for B-cell Lymphoma, with several candidates such as Lisocabtagene maraleucel in the advanced Phase III stage. DelveInsight’s “B-cell … Continue reading →

Liver Cancer Pipeline Grows as 70+ Pharma Companies Advance Novel Liver Cancer Therapies, Finds DelveInsight | Can-Fite BioPharma, Yiviva, Tvardi Therapeutics, Biosion, Novartis, Roche

Liver Cancer Pipeline Insight There are 70+ key companies, including Can-Fite BioPharma, Yiviva, Tvardi Therapeutics, Biosion, Novartis, Roche, and others, developing therapies for Liver Cancer, with Can-Fite BioPharma having its Liver Cancer drug candidate in the most advanced Phase III … Continue reading →

Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin

Antisense Oligonucleotide Therapeutics Pipeline Insights The Antisense Oligonucleotide landscape features 70+ key companies, including Novartis, Wave Life Sciences, Bio-Path Holdings, and others, advancing over 90 pipeline drugs. Companies like Novartis and Wave Life Sciences are currently leading with candidates in … Continue reading →

Global Ophthalmic Devices Market Set to Surpass USD 44 Billion by 2032, Driven by Rising Vision Disorders, AI Integration, and Expanding Geriatric Population | DelveInsight

Ophthalmic Devices Market The global ophthalmic devices market is entering a transformative growth phase, fueled by a surge in eye-related disorders, rapid technological innovation, and increasing global awareness around vision care. According to DelveInsight’s latest market intelligence report, the ophthalmic … Continue reading →

Non-Alcoholic Fatty Liver Disease Pipeline Shows Strong Momentum as 90+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and … Continue reading →

Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Marginal Zone Lymphoma Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and … Continue reading →

Small Cell Lung Cancer Clinical Trial Pipeline Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading →